2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1852 Duvelisib plus romidepsin as definitive therapy in relapsed/refractory peripheral T-cell lymphoma: Real-world outcomes in patients not intended for allogeneic hematopoietic cell transplantation

Christina Poh, MD, Cynthia Fu, PharmD2, Matthew Mei I, MD3, Geoffrey Shouse, DO PhD4, Steven T Rosen, MD5, Alex Francisco Herrera, MD6
1 City of Hope National Medical Center, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States

Background: Duvelisib plus romidepsin has demonstrated promising activity in relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). NCCN guidelines list this regimen primarily for patients intended for allogeneic hematopoietic cell transplantation (allo-HCT). This reflects trial and real-world evidence from cohorts enriched for patients bridged to allo-HCT, with survival analyses frequently censored at transplantation. Consequently, the effectiveness and tolerability of duvelisib plus romidepsin as definitive therapy without planned allo-HCT remain poorly defined. 

 Methods: We retrospectively identified patients with R/R PTCL treated with duvelisib plus romidepsin at the City of Hope National Medical Center (1/2020–7/2026) with definitive, non-bridging intent, and no planned consolidative allo-HCT. Overall and complete response rates (ORR, CRR) were investigator-assessed using Lugano criteria. Progression-free survival (PFS), overall survival (OS), duration of response (DOR), and time to next treatment (TTNT) were estimated using the Kaplan–Meier method. Treatment-emergent adverse events (TEAEs) were graded per CTCAE v5.0. Exploratory analyses evaluated associations between baseline clinical factors (age, hematopoietic cell transplantation–specific comorbidity index [HCT-CI], Prognostic Index for T-cell lymphoma [PIT] score, and histology) and treatment outcomes using two-sided Fisher exact tests.

Results: Among 50 patients with R/R PTCL treated with a duvelisib-containing salvage regimen, 26 (52%) received duvelisib plus romidepsin, of whom 19 (73%) were treated with definitive rather than bridging intent. Factors precluding allo-HCT included advanced age, comorbidity, patient preference, and other clinical considerations, including Jehovah's Witness status. In this cohort, the median age was 69 years (range, 43–93), and 10 (53%) were female. Race was White in 15 (79%), Asian in 3 (16%), and Black/African American in 1 (5%); 6 patients (32%) identified as Hispanic. Six patients (32%) had an HCT-CI ≥3. Histologies included nodal T-follicular helper (TFH) cell lymphoma (n=10, 53%), PTCL-NOS (n=7, 37%), ALK-negative anaplastic large cell lymphoma (n=1, 5%), and primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (n=1, 5%). Seventeen patients (89%) had stage III–IV disease, and the median number of prior lines of therapy was 2 (range, 1–5). Duvelisib was initiated at 75 mg BID in 9 patients (47%), 25 mg BID in 7 (37%), and 50 mg BID in 3 (16%). Median follow-up was 10.7 months. Patients received a median of 4.1 cycles of therapy (range, 0.2–33.3). ORR was 63%, including a CRR of 32%. Median DOR among responders was 7.1 months (95% CI, 1.5–NR). Median PFS was 6.8 months (95% CI, 3.3–11.8), median TTNT was 6.8 months (95% CI, 3.2–11.8), and median OS was 17.6 months (95% CI, 8.5–NR). Any-grade TEAEs were reported in 11 patients (58%), with grade ≥3 events in 4 (21%), including neutropenia, thrombocytopenia, mucositis, and opportunistic infections. Clinically significant infections occurred in 3 (16%) patients, including CMV viremia, invasive mucormycosis, and fungemia. Other notable toxicities included transaminitis (n=3), diarrhea (n=3), and anemia (n=3). Dose reductions occurred in 4 patients (21%), treatment interruptions in 9 (47%), and duvelisib discontinuation for toxicity in 4 (21%). No treatment-related deaths occurred. No significant associations were observed between age, HCT-CI, or PIT score and treatment outcomes. ORR was numerically higher among patients with nodal TFH cell lymphoma (78% vs 50%; p=0.35), and no patients with nodal TFH cell lymphoma had primary refractory disease.

Conclusions: Duvelisib plus romidepsin administered with definitive, non-bridging intent demonstrated clinically meaningful activity in R/R PTCL, with response rates and survival consistent with prior trial and real-world cohorts assessed without censoring at allo-HCT. The numerically higher response rate observed in nodal TFH cell lymphoma is consistent with prior reports, though this exploratory analysis was not powered to detect subgroup differences. Infectious complications, including CMV viremia and invasive fungal infections, were clinically significant and warrant close monitoring during therapy. 

Christina Poh, MD: Acrotech - Ended employment in the past 24 months; Corvus Pharmaceuticals - Research Funding; Secura Bio - Research Funding; Dren Bio - Research Funding; Incyte - Research Funding; Ono Pharmaceutical - Research Funding; Ascentage Pharma - Consultancy (Includes expert testimony); Acrotech - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)